Figure 2.
Management of acute BTH events in the OLE study. At the time of March 2022 data cut. ∗Patient had LDH >2× ULN and experienced an AE of BTH that was deemed related to PNH by the investigators. ꝉPatient had LDH >2× ULN and experienced an AE of anemia that was deemed related to PNH by the investigators. ‡Acute BTH event qualifying for administration of first round of intensive pegcetacoplan dosing. §Repeat acute BTH event treated with intensive pegcetacoplan dosing. BIW, twice weekly; BTH, breakthrough hemolysis; CAC, complement-amplifying condition; D, day; ECU, eculizumab; IV, intravenous; LDH, lactate dehydrogenase; PEG, pegcetacoplan; Q3D, every 3 days; RBC, red blood cell; SC, subcutaneous; TIW, 3 times weekly; ULN, upper limit of normal.

Management of acute BTH events in the OLE study. At the time of March 2022 data cut. ∗Patient had LDH >2× ULN and experienced an AE of BTH that was deemed related to PNH by the investigators. ꝉPatient had LDH >2× ULN and experienced an AE of anemia that was deemed related to PNH by the investigators. ‡Acute BTH event qualifying for administration of first round of intensive pegcetacoplan dosing. §Repeat acute BTH event treated with intensive pegcetacoplan dosing. BIW, twice weekly; BTH, breakthrough hemolysis; CAC, complement-amplifying condition; D, day; ECU, eculizumab; IV, intravenous; LDH, lactate dehydrogenase; PEG, pegcetacoplan; Q3D, every 3 days; RBC, red blood cell; SC, subcutaneous; TIW, 3 times weekly; ULN, upper limit of normal.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal